<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170623</url>
  </required_header>
  <id_info>
    <org_study_id>1160.33</org_study_id>
    <nct_id>NCT02170623</nct_id>
  </id_info>
  <brief_title>Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects</brief_title>
  <official_title>Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 2 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days in Healthy Subjects. Intraindividual Comparison (3-way Crossover) With and Without Pantoprazole, Randomised, Open.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the amount of BIBR 953 ZW in urine and concentrations in plasma after
      administration of 50 mg of BIBR 1048 bid over three days each administered as two
      experimental formulations relative to drinking solution with and without coadministration of
      40 mg Pantoprazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total amount of BIBR 953 ZW excreted into urine during one dosing interval (Ae0-12)</measure>
    <time_frame>Day 1 to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCss (Area under the plasma concentration-time curve at steady state) of BIBR 953 ZW</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum concentration at steady state) of BIBR 953 ZW</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from dosing to Cmax at steady state) of BIBR 953 ZW</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 12 hours after administration of study drug on day 3 of second treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Period 1: BIBR 1048 MS with Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) with 40 mg Pantoprazole (bid). Randomised sequence.
BIBR 1048 MS Capsule I with pantoprazole (bid for 3 days);
BIBR 1048 MS Capsule K with pantoprazole (bid for 3 days);
BIBR 1048 MS Drinking solution with Pantoprazole (bid for 3 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: BIBR 1048 MS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) without Pantoprazole. Fixed sequence.
BIBR 1048 MS Capsule K (bid for 3 days);
BIBR 1048 MS Drinking solution (bid for 3 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS Capsule I</intervention_name>
    <description>25 mg BIBR 1048 MS</description>
    <arm_group_label>Period 1: BIBR 1048 MS with Pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS Capsule K</intervention_name>
    <description>50 mg BIBR 1048 MS</description>
    <arm_group_label>Period 1: BIBR 1048 MS with Pantoprazole</arm_group_label>
    <arm_group_label>Period 2: BIBR 1048 MS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg pantoprazole</description>
    <arm_group_label>Period 1: BIBR 1048 MS with Pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS drinking solution</intervention_name>
    <description>50 mg BIBR 1048 MS powder plus solution</description>
    <arm_group_label>Period 1: BIBR 1048 MS with Pantoprazole</arm_group_label>
    <arm_group_label>Period 2: BIBR 1048 MS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects as determined by results of screening

          -  Signed written informed consent in accordance with GCP and local legislation

          -  Age ≥ 18 and ≤ 55 years

          -  BMI ≥ 18.5 and ≤ 29.9 kg/m2

        Exclusion Criteria:

          -  Any finding at the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          -  History of relevant orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  Chronic or relevant acute infections

          -  History of

               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
                  trial as judged by the investigator

               -  any bleeding disorder including prolonged or habitual bleeding

               -  other hematologic disease

               -  cerebral bleeding (e.g. after a car accident)

               -  commotio cerebri

          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

          -  Use of any drugs that might influence the results of the trial within 10 days prior to
             administration or during the trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the clinically accepted reference range

          -  History of any familial bleeding disorder

          -  Thrombocytes &lt; 150000/µl
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

